Stocks · News reference
KEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minuteMerck (NYSE:MRK), known as MSD outside of the United
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.
The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on high-quality dividend-paying stocks positions it well for further gains.
In HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier